Skip to main content

Table 1 Baseline patient characteristics according to the expression level of NCALD in TCGA CN-AML patients

From: High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia

Characteristics

Level

NCALD-low

NCALD-high

P-value

n

 

20

55

 

Sex (%)

Female

8 (40.0)

30 (54.5)

0.305

Male

12 (60.0)

25 (45.5)

 

Race (%)

Black

0 (0.0)

3 (5.5)

0.54

Others

0 (0.0)

1 (1.8)

 

Unknown

2 (10.0)

11 (20.0)

 

White

18 (90.0)

40 (72.7)

 

FAB (%)

M0

0 (0.0)

3(5.5)

0.9

M1

8 (40.0)

16 (29.1)

 

M2

4 (20.0)

15 (27.3)

 

M4

4 (20.0)

11 (20.0)

 

M5

4 (20.0)

8 (14.5)

 

M7

0 (0.0)

1 (1.8)

 

Unknown

0 (0.0)

1 (1.8)

 

Age (mean (sd))

 

51.15 (15.79)

55.80 (17.47)

0.3

BM_BLAST (mean (sd))

 

75.45 (15.39)

69.02 (19.16)

0.181

WBC (mean (sd)) × 109/L

 

56.91 (53.67)

49.00 (57.14)

0.592

PB_BLAST (mean (sd))

 

48.00 (36.32)

43.36 (32.46)

0.598

Karyotype (%)

Normal

20 (100.0)

55 (100.0)

NA

Risk (%)

Intermediate

20 (100.0)

55 (100.0)

NA

Induction (%)

7 + 3

8 (40.0)

23 (41.8)

0.852

7 + 3+3

6 (30.0)

13 (23.6)

 

7 + 3+3 + others

2 (10.0)

1 (1.8)

 

7 + 3+others

2 (10.0)

6 (10.9)

 

Cytarabine

0 (0.0)

1 (1.8)

 

Decitabine

2 (10.0)

3 (5.5)

 

Decitabine + others

0 (0.0)

1 (1.8)

 

Hydrea + others

0 (0.0)

1 (1.8)

 

No treatment

0 (0.0)

1 (1.8)

 

Others

0 (0.0)

1 (1.8)

 

Revlimid

0 (0.0)

4 (7.3)

 

Transplant (%)

Auto

3 (15.0)

1 (1.8)

0.34

Chemotherapy

10 (50.0)

27 (49.1)

 

Haplo

0 (0.0)

1 (1.8)

 

MUD

4 (20.0)

12 (21.8)

 

No treatment

0 (0.0)

1 (1.8)

 

sib Allo

3 (15.0)

13 (23.6)

 

Before_transplant (%)

CR 1

7 (35.0)

11 (20.0)

0.876

CR 2

2 (10.0)

5 (9.1)

 

CR 3

0 (0.0)

1 (1.8)

 

No transplant

10 (50.0)

27 (49.1)

 
 

No treatment

0 (0.0)

1 (1.8)

 

Others

1 (5.0)

7 (12.7)

 

Rel 1

0 (0.0)

2 (3.6)

 

Rel 2

0 (0.0)

1 (1.8)

 

Relapse (%)

No

14 (70.0)

14 (25.5)

0.001

Yes

6 (30.0)

41 (74.5)

 

DNMT3A (%)

Mutation

7 (35.0)

22 (40.0)

0.846

Unknown

0 (0.0)

1 (1.8)

 

WT

13 (65.0)

32 (58.2)

 

NPM1 (%)

Mutation

13 (65.0)

30 (54.5)

0.705

Unknown

0 (0.0)

1 (1.8)

 

WT

7 (35.0)

24 (43.6)

 

TET2 (%)

Mutation

4 (20.0)

5 (9.1)

0.443

Unknown

0 (0.0)

1 (1.8)

 

WT

16 (80.0)

49 (89.1)

 

FLT3 (%)

Mutation

7 (35.0)

23 (41.8)

0.71

Unknown

0 (0.0)

1 (1.8)

 

WT

13 (65.0)

31 (56.4)

 

IDH2 (%)

Mutation

1 (5.0)

9 (16.4)

0.464

Unknown

0 (0.0)

1 (1.8)

 

WT

19 (95.0)

45 (81.8)

 

IDH1 (%)

Mutation

4 (20.0)

5 (9.1)

0.443

Unknown

0 (0.0)

1 (1.8)

 

WT

16 (80.0)

49 (89.1)

 

RUNX1 (%)

Mutation

0 (0.0)

7 (12.7)

0.228

Unknown

0 (0.0)

1 (1.8)

 

WT

20 (100.0)

47 (85.5)

 

NRAS (%)

Mutation

3 (15.0)

3 (5.5)

0.512

Unknown

0 (0.0)

1 (1.8)

 

WT

17 (85.0)

51 (92.7)

 

WT1 (%)

Mutation

1 (5.0)

4 (7.3)

1

Unknown

0 (0.0)

1 (1.8)

 

WT

19 (95.0)

50 (90.9)

 

CEBPA (%)

Mutation

4 (20.0)

4 (7.3)

0.326

Unknown

0 (0.0)

1 (1.8)

 

WT

16 (80.0)

50 (90.9)

 

PTPN11 (%)

Mutation

1 (5.0)

4 (7.3)

1

Unknown

0 (0.0)

1 (1.8)

 

WT

19 (95.0)

50 (90.9)

 

KRAS (%)

Mutation

1 (5.0)

2 (3.6)

1

Unknown

0 (0.0)

1 (1.8)

 

WT

19 (95.0)

52 (94.5)

 
  1. n, number of patients; FAB, French–American–British subtypes; BM-blast, bone marrow blast; PB-blast, peripheral blood blast; WBC, white blood cell; MUD, matched unrelated donor; sib-allo HSCT, sib allogeneic stem cell transplantation; Haplo, haploidentical; CR 1, first complete remission; Rel 1, first relapse. Age, BM-blast, WBC and PB-blast statistical methods using unpaired t test, two sided. Use the Fisher’s exact test for statistical methods of categorical variables
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us